文献速递真菌感染

脂质体两性霉素B的临床药代动力学、药效学、安全性与疗效

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B.
PubMed 文献 · Clin Infect Dis · 2019-01-01

本文综述脂质体两性霉素B(LAmB)的临床药代动力学、药效学、安全性与疗效,覆盖多种患者人群与不同适应证,并评估需进一步临床研究的方向。

要点

  • LAmB仍是治疗多种酵母菌和霉菌所致侵袭性真菌病的重要药物。
  • 脂质体制剂旨在改善静脉两性霉素B耐受性并优化临床疗效。
  • 药代动力学与药效学认识持续演进,可用于优化疗效并维持安全性。

核心结论

  • LAmB仍是治疗多种酵母菌和霉菌所致侵袭性真菌病的重要药物。
  • 脂质体制剂旨在改善静脉两性霉素B耐受性并优化临床疗效。

研究设计与样本

  • 综述临床药代动力学、药效学、安全性与疗效,覆盖多种患者人群与不同适应证。

主要发现

  • 已有大量临床研究积累LAmB在临床前与临床中的疗效、安全性和耐受性证据。
  • 对LAmB药代动力学与药效学的认识持续演进,可用于制定优化疗效并维持安全性的策略。

临床怎么用

  • 可将LAmB药代动力学与药效学认识用于制定优化疗效并维持安全性的策略。

局限性

  • 部分领域仍需进一步临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since its introduction in the 1990s, liposomal amphotericin B (LAmB) continues to be an important agent for the treatment of invasive fungal diseases caused by a wide variety of yeasts and molds. This liposomal formulation was developed to improve the tolerability of intravenous amphotericin B, while optimizing its clinical efficacy. Since then, numerous clinical studies have been conducted, collecting a comprehensive body of evidence on its efficacy, safety, and tolerability in the preclinical and clinical setting. Nevertheless, insights into the pharmacokinetics and pharmacodynamics of LAmB continue to evolve and can be utilized to develop strategies that optimize efficacy while maintaining the compound's safety. In this article, we review the clinical pharmacokinetics, pharmacodynamics, safety, and efficacy of LAmB in a wide variety of patient populations and in different indications, and provide an assessment of areas with a need for further clinical research.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Groll AH, Rijnders BJA, Walsh TJ, et al. Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clin Infect Dis. 2019. PMID: 31222253. doi:10.1093/cid/ciz076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。